Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia

Standard

Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia. / Löbel, U; Trah, J; Escherich, G.

in: PEDIATR BLOOD CANCER, Jahrgang 62, Nr. 3, 03.2015, S. 539-41.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{0533842417834903993028958b9af5b3,
title = "Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia",
abstract = "Systemic and intrathecal methotrexate is widely used in treatment protocols for childhood acute lymphoblastic leukemia. Its side effects vary in characteristics, intensity and time of onset, and depend on the administration route. Interactions with several drugs are known. Side effects of nitrous oxide sedation, often used for moderately painful procedures, typically occur after long time use and include neurological symptoms. We present a child who experienced a severe and long-lasting neurotoxicity after the third intrathecal application of methotrexate with short sedation by nitrous oxide during induction therapy for acute lymphoblastic leukemia. Symptoms completely resolved after 12 months.",
keywords = "Analgesics, Non-Narcotic, Child, Female, Humans, Immunosuppressive Agents, Injections, Spinal, Intracranial Hemorrhages, Methotrexate, Neurotoxicity Syndromes, Nitrous Oxide, Precursor Cell Lymphoblastic Leukemia-Lymphoma",
author = "U L{\"o}bel and J Trah and G Escherich",
note = "{\textcopyright} 2014 Wiley Periodicals, Inc.",
year = "2015",
month = mar,
doi = "10.1002/pbc.25270",
language = "English",
volume = "62",
pages = "539--41",
journal = "PEDIATR BLOOD CANCER",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia

AU - Löbel, U

AU - Trah, J

AU - Escherich, G

N1 - © 2014 Wiley Periodicals, Inc.

PY - 2015/3

Y1 - 2015/3

N2 - Systemic and intrathecal methotrexate is widely used in treatment protocols for childhood acute lymphoblastic leukemia. Its side effects vary in characteristics, intensity and time of onset, and depend on the administration route. Interactions with several drugs are known. Side effects of nitrous oxide sedation, often used for moderately painful procedures, typically occur after long time use and include neurological symptoms. We present a child who experienced a severe and long-lasting neurotoxicity after the third intrathecal application of methotrexate with short sedation by nitrous oxide during induction therapy for acute lymphoblastic leukemia. Symptoms completely resolved after 12 months.

AB - Systemic and intrathecal methotrexate is widely used in treatment protocols for childhood acute lymphoblastic leukemia. Its side effects vary in characteristics, intensity and time of onset, and depend on the administration route. Interactions with several drugs are known. Side effects of nitrous oxide sedation, often used for moderately painful procedures, typically occur after long time use and include neurological symptoms. We present a child who experienced a severe and long-lasting neurotoxicity after the third intrathecal application of methotrexate with short sedation by nitrous oxide during induction therapy for acute lymphoblastic leukemia. Symptoms completely resolved after 12 months.

KW - Analgesics, Non-Narcotic

KW - Child

KW - Female

KW - Humans

KW - Immunosuppressive Agents

KW - Injections, Spinal

KW - Intracranial Hemorrhages

KW - Methotrexate

KW - Neurotoxicity Syndromes

KW - Nitrous Oxide

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

U2 - 10.1002/pbc.25270

DO - 10.1002/pbc.25270

M3 - SCORING: Journal article

C2 - 25360802

VL - 62

SP - 539

EP - 541

JO - PEDIATR BLOOD CANCER

JF - PEDIATR BLOOD CANCER

SN - 1545-5009

IS - 3

ER -